7092DMT08Poster-Disease-modifying TherapyXavier Montalban Archives - 2021 CMSC Annual Meeting

2021 CMSC Annual Meeting

Tag: 7092DMT08Poster-Disease-modifying TherapyXavier Montalban

Poster-Disease-modifying Therapy

October 25, 2021

Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...

Read More →

MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US

© 2021 CMSC